Sorry, you need to enable JavaScript to visit this website.

All announcements

Announcement Date

Dear Health Care Provider Letter


Dear Health Care Professional, Pfizer is pleased to inform you that the QuilliChew ER (methylphenidate HCl) chewable tablet supply issue has been resolved and QuilliChew ER is available to patients as appropriate. As for Quillivant XR (methylphenidate HCI) oral suspension, there is still supply shortage for this product. Pfizer is working diligently to resolve the supply, however the duration of the supply shortage is unknown at this time. In the interim, health care professionals should use their clinical expertise to determine the best treatment for their patients.
January 29, 2018

Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published in the New England of Medicine Demonstrate the Vaccine's Immunogenicity

December 14, 2017

US Food and Drug Administration Extends Action Date for Xeljanz (Tofacitinib) Supplemental New Drug Application in Ulcerative Colitis by Three Months

December 13, 2017

Greenstone Issues Voluntary Recall of Diphenoxylate HCl and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets

November 21, 2017

Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)


Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG is the first therapy with an indication that includes pediatric AML. It is also the only AML therapy that targets CD33, an antigen expressed on AML cells in up to 90% of patients.
September 12, 2017

Overview of Quillivant XR (video presentation)

February 22, 2017

Overview of QuilliChew ER (video presentation)

February 22, 2017